Dennis. Thanks,
for recent across some for through past plans our upcoming let as now So well business weeks, the of run months. key updates the me as quarter from
heartburn. as quick cancers, So start with focused earliest stages. of developing let's commercial cancer, company who unlike in highly esophageal even just mortality chronic other lucid at com stage always, lucid diagnostics its diagnostics are is a lethal Patients prevention risk this millions are the rates as intro, high cancer, common cancer a at on
requires in to be procedure detect pre-cancer pre-cancer, deaths endoscopic esophageal preventing of which with five in esophageal approximately occurs us and chronic which Patients in reliably at phase monitored esophageal late XX% So its cancer. its can risk phase, to cured an heartburn. early halts progression to
screening been esophageal invasive the profound been undergone could available serving a pre-cancer a prevent at-risk patients device patient had PR screening, viable samples to the heartburn believe curative Although in esophageal widespread been front and performed heart capable Lucid. millions of is traditional death T through test first tool have pre-cancer the tests can then the screening on of with only tool such the detection fewer is if cancer chronic We of program chronic XX% treatment, check likely already commercially esophageal a than tragedy detect of of that a undergo cancer the esophageal commercial widespread lack pre-cancer. that prevention in an esophageal that endoscopic these patients the recommended constitute of elements has death for early diagnostic and cancer monitoring on a missing esophageal screened prevented and screening diagnosis widespread
each check patient, XX Lucid sent ESO esophagus, collect surface that then practitioner assistant lucid Lucid and personnel a sales increase and and check for its or a per non-invasive precancer, estimates clinical that cover week, the per ESO force, sales sales in program from in with now hired self-refer by Each test cities of cities, personnel program program, launch practitioner for August test in sales day, and its centers regional its is test are of esophageal Egar before couple months pilot the major chronic to the to independent the the Lucid hybrid its just expanding are now the primary fold based this their who and in IPO launched its past testing. physician direct process is a from progresses single covering with nurse expanding undergo also for a elusive midst City medical in and nurse in heartburn can the dedicated Southwest support employed center Lake Phoenix of Salt patients centers Denver, costs and who which the an, model, utilizing infrastructure Several the Las elusive us from Pacific the to these look a to will test to commercial esophageal the a only care is expects in Western next cities uses which it PCP forward XX of of rapidly who program's across then the we procedures staffed week, up from, these Vegas. growth, sales office headcount. expects from XXXX office rapid to recent Last test cancer. the on center rep steady Northwest thereafter. tests can cells flush a and in with proceeds to focus phase moving full-time Now test expansion commercial medical by has deadly to estimates referred perform advanced nationwide of
Our that experience attractive over three and Phoenix center past each months again modest the costs in demonstrated margins. fixed has test be can operated
centers ups the the script. to just closely call we in in that on last is place pharmaceutical physic the did test We key recruit driven Egar the working these who driving them cities been as care we have launch and referrals of sectors representatives launched week, experienced three new at with Lucid also has diagnostics from to primary exclusively care highly also most physicians or primary the learned sales
finalizing consumer which testing will independent Our accommodate ups from telemedicine branded to Lucid partner to marketing. platform, for direct is the telemedicine self-referrals script Egar
pilot telemedicine while Lucid direct in primary a with in So weeks, Lucid referrals consumer on sales focused Salesforce Egar program Phoenix Egar to increasingly test care coming continues program as and to will to commercialization drive launch physician transforming a centers. in the this to infrastructure direct training marketing growing fundamentally
of expansion human we a transitional to increasingly and a and quarter care other. resources somewhat sales these was The third Salesforce to including Showpad we primary the focused our physicians on salesforce.com direct and implementing dedicated quarter infrastructure, moved as of
very in basis. XXX% testing We on to month at robust completed transitional the this are and five intensive during sales flat a quarter -- trading also was graduates up program on most volume during quarter, this over the annual XXX calling transition but an established physicians process tests recent relative day and of prior the XXX now field last
front We I the a continue became to EsoGuard Medicare January. effective payment mentioned which last national see as slow already, has but of previously steady reimbursement progress in secured rate on $X,XXX,
for chronic discussion included the very which cancers, esophageal multi advisor top gastrointestinal a committee on encouraged stir risk to on screening support focused Our on DX thus of as on gastroenterologist panel however, the beginning on the, determination of contractor, voiced with a current Medicare we Paul certain the been since We last the efforts GBA although of on coverage slowed Medicare XXXX, X program coverage have or final private were reason testing. related secured the securing program of determination engaged payment payment held and by that significant effective front for are meadow, mold well testing things the strong have early payer topic expert patients. that and pandemic month, precancer and CAC coverage contractor backlog high Medicare do as the coverage and reviews. administrative believe we coverage, payment molecular meeting coverage, heart been we We public Egar has to are
alignment XX% for payment some standard out encouraging however, course, averaging and increasingly such contracts requires a network. is negotiating from critical and volumes network major term Arizona successful and where with multi this regional programs, some over held payers had, process volume we've months we local which such with that the prerequisite process Our insurers, along including reimbursement we with a private payer of private a the payers certain test. will see directors bottom private clinical decision engagements to making. we contact approach. dollars payer which to a advisory board the longer close coverage impacts The data with constantly with indicated also a claims in coverage payer message each Most Egar in access demonstrating undergo have, consultants expert focused one determination market this in reimbursement are submitted to the might that medical two we are coming major with with the interim on endoscopy. of a good securing that clinical continues and message of Egar initiated national per be positively tests utility past notably initiating reach reinforce draft meetings, meetings now reaching hopeful the patients September that from on and our test, of Don't on payments and X laboratory to receive in engaging have in team our payers is thousand that these with private side, Private have strategic is negative locals performed line
provide registry clinical soon will We busiest are our also in own sites such have such data our utility clinical clinical data. collecting from which place, will and
related have research which current partner agreed newly Lucid I'd the subsidiary labs which of principle on the terms a Next Lucid and research substantial own lucid created DX agreement Egar hopefully that the only Lucile test launching will defend made recently laboratory. our and DX before would some the labs. executing spend and DX research payers the the the eliminate to test. test the performance securing to certified separate process Clea into DX to laboratory, through would like Irvine a lease in look acquire and DX would and Lucid the a of the agreements continue end progress Lucid forward to to complexities the bill Egar of Lucid certificate perform We owned time to with by directly clear licenses DX in management the labs building allow year in Lucid manage services for we've involving
to VP Dr. Soon there, Verma a much accomplished been services once and officer, role as Lucid in a our of in progressing commercially Things of more case her could well test and also own and position transferring highly launch family excited effort laboratory has Egar laboratory prior Egar coming DX are launching months. in and clinical developed board her not a Luci on at search assay appointed as thereafter the the part newly research the available on sum central Verma. has the been have meeting, molecular development from of clear Western laboratory be program. research chief side biologists her to she genomic the scientific played the
and an not, international with sites tube are FDA And inviro the the European check The is of We portfolio. FDA moving before us precancer. support of rest the end despite sites all are and couple the studies two active detect of highlights to diagnostic steady indicated sites loose earliest clinical XXXX, have currently approval submission by guard XXXX more to XX B dual of is with use in Europe is multicentered the enrollment still enrollment nine BX and has us patients in enrolling PMA targeting to COVID. of and on and completion we PMA XX trials. actively
in in the sponge esophageal We next, at with sciences are which list formal diagnostics awarded industry. program, pre-cancer European month, accolades Lucid over quality life biotech car. different to major world biotech early discussions tunnel esophagal EsoGuard non been adopters, of innovation relationships at nominations award the commenced medical the proud invasive recognizing a update minimal esophageal optimistic what endoscopic building corner Carp Neo constantly eight the I'm The commercial manager with as lab our recent innovation scheduled frustrating manufactures systems device caps, our has in and excellent North the pre-commercial orthopedic annual we and XX have at five Mayo to sponsors trained an recruit weeks, doing quarter manufacturing mark commercial treat Carolina research than throughout surgery an during challenges, and syndrome. training which acquired launch and his C SCH and turn medical procedures surgeons their a additional past this of on see scheduled think honors five brief have started lucid period with seven being currently the based XX surgeons at certified year complete have and cadaver and products with at of is job he repeated breakthroughs hand to bus. been biomarkers last attracted add of four carpal clinical the another us actually a recruiting limited National nearly motivated remains June, centers tunnel after sales have and their clinical collection XXXX CarpX, related program leveraging of the a academic from with company, FDA the and used centers, to cases. full-time has manager are CarpX based territory support We hired carpal and global year's and time years also cell that more full LLC, and to including device, momentum countries to on Hopkins. in PAVmed in experience and a major we're academic John's space transition training performed since specialist starting year clinic cleared This
on and first next remain the this product, including step car generation although this just So, exciting upbeat device. a I'm is by progress and this the of groundbreaking encouraged about future progress
growing underlying its to Webb She technology of highly leaders, experience the successfully second improve sector. to acquired Veris pad's of Valley a teams software, majority executive of digital of owned team groundbreaking as data and undergoing phone now progress with I'll try analytics digital appointment generating biologic patients adverse services lab. in is encourage was as a wireless Let's of lo coding parameters in data as if accomplished well entry A service initial data as capable did, outcomes cancer symptom development including made platform. well watch in Silicon into and agreement various based smartphone you brings last represents Sunny is partnership since and sensors and physiologic, entered with the enterprise industry communications advanced to teams desktop now six clickable month. cloud-based firm And software months. decades in we've healthcare technologies, of a September Chief and a on, It are groundbreaking Last into as a apps, port device virus's contains VA the on patient's known Silicon proud Val and Oncodisc, this physiologic the and health digital we the LO's efficiently in was cutting reporting to dynamic hardware nearly key port Silicon Veris with platform. launching Technology In Phillips, are access intelligent brief and our personalized sensors products, expertise the The launch has and to functions, now structures. completed recording. event be first effectively. it advanced treatment various integrates Facebook. you and the health worked, investor of of intelligence cancer of acquisition, Garris I for access Since telehealth highlight of full of making global level predict program company half side the smartphone Officer. the participated successfully to to really valley with tools month next deep dozens cancer with continuous of virtual subsidiary platform both data move realtime health will implantable an various software remote advancing access accepted building major care leading learning, actionable implantable Veris healthcare, recent development a patients digital for went remote of many intelligent interface Veris platform. clearance the Microsoft's vascular targeting now excellent developing platform with Veris care. seek technology, the I'm on vascular leading that with FDAX, the is year. you the science, apple, digital two remote and which board She a data analytics, user port animal hall, and software the pad progress edge and central the and very of our well. to implantable remarkable and are the as rapidly healthcare and rapidly into deliver such machine physicians
the of and advisory of have Silicon apply chronic two with leaders announcing D a advisory technologies and seeks very launched in the to country be across major effort finally, soon recently, boards various patients technology We COPT. a of heart This most lung to conditions and advisory various kidney prevalent care enhance failure, major important key, board opinion key including will R valley. medical and we and beyond cancers or the care, cancer board Illuminaries cancer. failure, disease, to project the
the performed seeks and revolutionize which million pumps of error next need including X each day. level, on most by for set, low care in electronic prone expensive infusions our IV infusion the to next country this Mo complex Now eliminating for
our plague spared, the timeline. as of certain company us able much been the haven't China. delay supplier, a We were supply next of issues, months of heard chain brunt to certain eventually we've a the we a US the the of component switch cost to Although but receipt country, in some in the delay couple from
pushed target QX in valley received FDA we've We FDA now the our our date verification have for but parts in starting to of XXXX. testing submission submission,
to we're a for in pad very, next capital. to personnel company supply we value low a next needed as very and strategic I pad cash the position, case is long are which pre-commercial strategic low and asset, has of over exposed several Maxwell and still for the commercial necessary. recruitment we of commercialize from sales market, been commercial years, with in been anticipation a And year, today slow. our receive that than a has strong We're IPO. different next the a obviously significantly although next which we're then this we can in not me that entertaining many shareholders much know a already from strong offers, we are commercial we following leadership were continue flow happy have, to term pre-commercial these the approach excuse valuable interest create in organically to especially next that if be the open a to commercial for product very positioning engagements however launching then, period. will, were the engagements we painfully in however to are, space, low is time that leading Back should our now to launch me we acquisition product low me, to continuing of product obviously know the has note We the evolved next
plan few brief the remain Finally, our local highlights and long a slow. of human frustratingly due device products our IRB of the study but The in iNOS progress port from sake remains to a America on other portfolio few time, access for in not implantable backlogs. all vascular delayed Columbia, IO, south
we'll of us to considering CE classic are in due finally challenges to that continues Europe. reverting FDA year strategy implant after signs support and we IO the on study, the the alone mark be promising strongly they're However, in term and MedTech able start launching us, long patients the a ID to seeking present with us east
our in most we looked clearance devices to study, well, which for ablation in head the head with included secure continue things great. a comparisons XXXX. recent be expect K and our to bear position histopathology If XX he really submit progressing Medtronic from go First, animal well, five, data to esophageal extremely to his
you now attention. and can operator, all your And you call for your thank really thank the attention. we that for questions So with open to
